Interferon alfa-2b

Interferon alfa-2b
Clinical data
MedlinePlus a690006
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		 Subcutaneous, intramuscular
    ATC code
    Legal status
    Legal status
    Identifiers
    IUPHAR/BPS
    DrugBank
    ChemSpider
    • none
    ChEMBL
    ECHA InfoCard 100.208.165 Edit this at Wikidata
     ☒N☑Y (what is this?)  (verify)

    Interferon alfa 2b is an antiviral or antineoplastic drug, that was originally discovered in the laboratory of Charles Weissmann at the University of Zurich. It was developed at Biogen, and ultimately marketed by Schering-Plough under the tradename Intron-A. It has been used for a wide range of indications, including viral infections and cancers.

    This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, Behçet's disease, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, mastocytosis and malignant melanoma.

    Interferon alfa-2b products[1]
    Product Manufacturer Features Special uses
    Alpharona Pharmaclon
    Intron-A/IntronA Schering-Plough
    Realderon Teva
    Reaferon EC GNC Vector
    Reaferon EC-Lipint Vector-Medica liposomal
    Infagel Vector-Medica ointment
    Recolin Vector-Medica
    Altevir Bioprocess subsidiary liquid, free of HSA
    Kipferon Alfarm combination with IgM, IgA, IgG
    Giaferon A/S Vitafarma
    Genferon Biocad
    Opthalamoferon Firn-M with dimedrol eye infections

    See also

    References

    1. ↑ Dmitrij I. Bairamashvili1 and Mikhail L. Rabinovich2* (2007). "Russia through the prism of the world biopharmaceutical market" (PDF). Biotechnol. J. 2.
    • Intron-A Summary of Product Characteristics
    • Nagata S, Taira H, Hall A, et al. (Mar 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature. 284 (5754): 316–20. doi:10.1038/284316a0. PMID 6987533.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.